Supplementary Figure 1 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Figure 1. Eight-year estimates, in an intention-to-treat analysis, for OS (solid line) and TFS (dashed line) in 272 CML patients receiving IM 400 mg/daily as first line therapy. At 60 months, OS was 93%, while TFS was 97.5%. Vertical lines indicate censored patients.